← Back to Search

Other

IHT for Mild Cognitive Impairment

N/A
Recruiting
Research Sponsored by University of North Texas Health Science Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to breathe moderately hypoxic air via an air-cushioned, disposable facemask
Adult men and women ages 55 to 79 years old who have been diagnosed with MCI
Must not have
Have severe head injury or traumatic brain injury, stroke (hemorrhagic and/or ischemic)
Currently have COVID-19
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline 5-week, 8-week, and up to 12-week intervention

Summary

This trial will test whether a breathing program can help improve mild memory loss.

Who is the study for?
This trial is for adults aged 55-79 with mild cognitive impairment (MCI). Participants must be depression-free, post-menopausal if female, have certain stable chronic conditions, and able to visit the lab. Exclusions include major upcoming surgery, current severe illnesses like uncontrolled hypertension or diabetes, recent high-altitude living, metal implants, or claustrophobia to facemasks.
What is being tested?
The study tests intermittent hypoxia training (IHT) versus a sham control over 12 weeks to see if it's safe and effective for improving memory in people with MCI. Participants will breathe moderately hypoxic air through a mask and are randomly assigned to either the treatment or placebo group.
What are the potential side effects?
Potential side effects of IHT may include discomfort from wearing a facemask and reactions to breathing hypoxic air such as dizziness or headaches. Since this is an early-phase trial assessing safety, detailed side effect profiles will be determined during the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can breathe through a special mask with less oxygen.
Select...
I am between 55 and 79 years old and have been diagnosed with mild cognitive impairment.
Select...
I am a woman and have gone through menopause.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a severe head or brain injury, or a stroke.
Select...
I currently have COVID-19.
Select...
I do not have uncontrolled chronic conditions like high blood pressure or diabetes.
Select...
I am expecting to undergo major surgery or receive a transplant.
Select...
I cannot go to the lab by myself.
Select...
I am not willing to sign consent for a double-blinded trial.
Select...
I have been diagnosed with depression recently.
Select...
I have been diagnosed with Alzheimer's dementia or struggle with daily tasks due to my condition, and my mental exams show advanced impairment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline 5-week, 8-week, and up to 12-week intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline 5-week, 8-week, and up to 12-week intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Memory
Cognitive Function
Overall Cognitive Function
+1 more
Secondary study objectives
Brain Morphology
Cerebral Vascular Function
Neuroprotective Protein
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IHT TreatmentExperimental Treatment1 Intervention
Exposures to hypoxic air (10% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
Group II: Sham-IHT controlPlacebo Group1 Intervention
Exposures to normoxic air (21% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterOTHER
1,080 Previous Clinical Trials
1,056,247 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,785 Previous Clinical Trials
28,184,670 Total Patients Enrolled
University of North Texas Health Science CenterLead Sponsor
40 Previous Clinical Trials
20,702 Total Patients Enrolled

Media Library

IHT Treatment (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05495087 — N/A
Mild Cognitive Impairment Research Study Groups: Sham-IHT control, IHT Treatment
Mild Cognitive Impairment Clinical Trial 2023: IHT Treatment Highlights & Side Effects. Trial Name: NCT05495087 — N/A
IHT Treatment (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05495087 — N/A
~13 spots leftby Apr 2025